TWD 22.25
(0.23%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 854.37 Million TWD | 6.63% |
2022 | 618.05 Million TWD | -6.39% |
2021 | 660.25 Million TWD | 30.5% |
2020 | 505.93 Million TWD | -3.07% |
2019 | 521.95 Million TWD | 2.99% |
2018 | 506.79 Million TWD | -2.18% |
2017 | 518.09 Million TWD | 5.15% |
2016 | 492.7 Million TWD | -4.79% |
2015 | 517.48 Million TWD | 6.14% |
2014 | 487.57 Million TWD | 7.33% |
2013 | 454.25 Million TWD | -7.01% |
2012 | 488.47 Million TWD | -8.23% |
2011 | 532.31 Million TWD | -13.17% |
2010 | 613.05 Million TWD | -1.94% |
2009 | 625.18 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 171.28 Million TWD | -13.04% |
2024 Q1 | 196.96 Million TWD | 5.6% |
2023 Q2 | 159.6 Million TWD | -0.62% |
2023 Q1 | 160.6 Million TWD | -4.51% |
2023 Q4 | 186.52 Million TWD | 22.47% |
2023 Q3 | 152.29 Million TWD | -4.58% |
2023 FY | 659.02 Million TWD | 6.63% |
2022 Q1 | 160.73 Million TWD | -14.63% |
2022 Q3 | 152.29 Million TWD | 11.29% |
2022 FY | 618.05 Million TWD | -6.39% |
2022 Q4 | 168.18 Million TWD | 10.43% |
2022 Q2 | 136.84 Million TWD | -14.86% |
2021 FY | 660.25 Million TWD | 30.5% |
2021 Q1 | 137.9 Million TWD | -0.62% |
2021 Q2 | 151.53 Million TWD | 9.88% |
2021 Q3 | 182.55 Million TWD | 20.47% |
2021 Q4 | 188.26 Million TWD | 3.13% |
2020 FY | 505.93 Million TWD | -3.07% |
2020 Q2 | 117.54 Million TWD | 2.31% |
2020 Q1 | 114.88 Million TWD | -12.09% |
2020 Q3 | 134.72 Million TWD | 14.61% |
2020 Q4 | 138.77 Million TWD | 3.0% |
2019 Q1 | 143.22 Million TWD | 8.42% |
2019 Q3 | 117.21 Million TWD | -10.4% |
2019 Q4 | 130.69 Million TWD | 11.5% |
2019 FY | 521.95 Million TWD | 2.99% |
2019 Q2 | 130.82 Million TWD | -8.66% |
2018 FY | 506.79 Million TWD | -2.18% |
2018 Q2 | 122.62 Million TWD | -9.12% |
2018 Q1 | 134.92 Million TWD | 5.36% |
2018 Q4 | 132.09 Million TWD | 12.76% |
2018 Q3 | 117.15 Million TWD | -4.46% |
2017 Q2 | 130.47 Million TWD | 0.63% |
2017 Q3 | 129.89 Million TWD | -0.44% |
2017 FY | 518.09 Million TWD | 5.15% |
2017 Q1 | 129.65 Million TWD | 10.24% |
2017 Q4 | 128.06 Million TWD | -1.41% |
2016 Q3 | 123.79 Million TWD | 0.71% |
2016 FY | 492.7 Million TWD | -4.79% |
2016 Q4 | 117.62 Million TWD | -4.99% |
2016 Q2 | 122.92 Million TWD | -4.23% |
2016 Q1 | 128.36 Million TWD | 2.33% |
2015 Q2 | 132.27 Million TWD | 4.11% |
2015 Q1 | 127.05 Million TWD | 5.82% |
2015 FY | 517.48 Million TWD | 6.14% |
2015 Q4 | 125.43 Million TWD | -5.49% |
2015 Q3 | 132.72 Million TWD | 0.34% |
2014 Q3 | 135.65 Million TWD | 14.84% |
2014 Q2 | 118.12 Million TWD | 3.85% |
2014 FY | 487.57 Million TWD | 7.33% |
2014 Q1 | 113.73 Million TWD | 14.92% |
2014 Q4 | 120.05 Million TWD | -11.5% |
2013 Q4 | 98.97 Million TWD | -5.08% |
2013 Q2 | 122.02 Million TWD | -5.32% |
2013 Q3 | 104.27 Million TWD | -14.55% |
2013 FY | 454.25 Million TWD | -7.01% |
2013 Q1 | 128.87 Million TWD | 25.75% |
2012 Q4 | 102.49 Million TWD | -20.31% |
2012 Q1 | 126.67 Million TWD | 8.15% |
2012 Q2 | 130 Million TWD | 2.63% |
2012 Q3 | 128.61 Million TWD | -1.07% |
2012 FY | 488.47 Million TWD | -8.23% |
2011 FY | 532.31 Million TWD | -13.17% |
2011 Q3 | 132.16 Million TWD | -3.9% |
2011 Q2 | 137.52 Million TWD | -5.49% |
2011 Q1 | 145.5 Million TWD | -13.22% |
2011 Q4 | 117.12 Million TWD | -11.38% |
2010 Q3 | 149.88 Million TWD | -0.75% |
2010 Q2 | 151.01 Million TWD | 4.52% |
2010 FY | 613.05 Million TWD | -1.94% |
2010 Q1 | 144.48 Million TWD | 0.0% |
2010 Q4 | 167.67 Million TWD | 11.87% |
2009 FY | 625.18 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Grape King Bio Ltd | 6.03 Billion TWD | 85.853% |
Standard Chem & Pharm CO., LTD. | 1.46 Billion TWD | 41.714% |
ScinoPharm Taiwan, Ltd. | 901.49 Million TWD | 5.228% |
Lotus Pharmaceutical Co., Ltd. | 4.48 Billion TWD | 80.933% |
LIWANLI Innovation Co., Ltd. | 54.86 Million TWD | -1457.198% |
YungShin Global Holding Corporation | 2.04 Billion TWD | 58.277% |
PhytoHealth Corporation | 67.64 Million TWD | -1163.06% |
SCI Pharmtech, Inc. | 190.02 Million TWD | -349.615% |
Formosa Laboratories, Inc. | 1.24 Billion TWD | 31.56% |
PharmaEssentia Corporation | 4.49 Billion TWD | 80.993% |
Bora Pharmaceuticals Co., LTD. | 1.74 Billion TWD | 50.957% |